Advisory Board
Gastrointestinal Care
Henry J. Binder, MD
Board AdvisorProfessor Emeritus of Medicine, Senior Research Scientist, Yale University
Jervoise Adreyev, MD, PhD
Board AdvisorRoyal London Hospital, PHD in molecular biology from the Institute of Cancer Research. First gastroenterologist appointed specifically to treat the side effects of cancer treatments.
Olivier Fontaine, MD, MS, FACP
Board AdvisorMedical Officer for World Health Organization in the Diarrheal Diseases Control Program. MD, University Paris V MS in Molecular Biology, University Paris VI Jussieu
Oncology
Jerrold R. Turner, MD, PhD
Board AdvisorDr. Turner has, for over 25 years, led an NIH- and foundation-funded research program focused on gastrointestinal mucosal barrier function. The goals of this program are to understand the molecular mechanisms that build and maintain mucosal barriers to define the impact of barrier regulation and dysregulation on health and disease. His work has led to fundamental advances that have generated new paradigms of mucosal barrier regulation in gastrointestinal physiology and pathobiology. Turner’s group has built on these discoveries to develop novel, molecularly-targeted therapeutics that restore mucosal barrier function and shown that these agents can both prevent and treat experimental disease.
Stephen E. Finkelstein, MD, FACRO
Board AdvisorCancer Center Director, BRCC Co-Chair, NRG Immunotherapy Committee and Chair, SWOG Radiation STG Committee Senior Director, ASTRO eContouring and Co-Chair, 2018 ACRO Scientific Program Committee Editor-in-Chief, Contemporary Radiation Oncology and Editor, ASCO Publications
Paul Okunieff, MD
Board AdvisorPaul Okunieff, MD, is board-certified in therapeutic radiology and is among the pioneers of in-vivo nuclear magnetic resonance imaging of tumors. Dr. Okunieff’s research includes development of a novel method to measure radiation-induced DNA fragments in the bloodstream to estimate radiation exposure, and the identification of molecules that provide genetically-based protection against radiation hazards. He has active protocols to study the treatment of metastatic cancers with radiosurgery and is developing protocols for the use of proton therapy in metastatic cancers.
Charles F. Fuchs, MD, MPH
Board AdvisorDr. Fuchs is the Director of Yale Cancer Center, Physician-in-Chief of Smilow Cancer Hospital, and the Sacker Professor of Medicine at the Yale School of Medicine. An internationally recognized expert in gastrointestinal cancers, cancer treatment, and cancer prevention, Dr. Fuchs was most recently a Professor of Medicine at Harvard Medical School and Chief of the Gastrointestinal Oncology Division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute.
Pulmonary
Bruce Levy, MD
Board AdvisorDr. Levy is the Parker B. Francis Professor of Medicine at Harvard Medical School and Chief of the Pulmonary and Critical Care Medicine Division at Brigham and Women’s Hospital. Dr. Levy’s laboratory aims to identify new pathways to resolve pulmonary inflammation, infection or injury through the roles of naturally-derived, specialized pro-resolving mediators, and to translate these findings to the pathobiology of important airway diseases. His work has helped lead to more than 175 peer-reviewed publications, over 10 patents awarded or pending, and continuous funding from the National Institutes of Health since 1993. He is currently a standing member of the NIH LCMI study section. He is an elected member of the ASCI, AAP and Interurban Clinical Club. He is active in the American Thoracic Society and currently serves as Chair of the Publication Policy Committee and member of the Board of Directors.
Cystic Fibrosis
Robert. J. Bridges, MD, PhDRobert. J. Bridges, MD, PhD
Board AdvisorDr. Robert J. Bridges Ph.D. is a professor of physiology and biophysics at Rosalind Franklin University of Medicine and Science. He is a member of the Center of Genetic Diseases as well as the Director of the Center for Cystic Fibrosis Drug Discovery. Dr. Bridges studies the physiology, biophysics and pharmacology of epithelial ion channels. The Bridges’ laboratory has assisted a number of pharmaceutical and biotech companies with their discovery and development of drugs for the treatment of Cystic Fibrosis.
Steven D. Freedman, MD, PhD
Board AdvisorSteven D. Freedman M.D., Ph.D. is Director of the Pancreas Center at Beth Israel Deaconess Medical Center, Chief of the Division of Translational Research, and Professor of Medicine at Harvard Medical School, Boston, Massachusetts. Dr. Freedman’s is an internationally recognized leader in exocrine pancreatic disease with a particular focus on pancreatitis and cystic fibrosis with an extensive research program that encompasses both basic science discovery as well as clinical trials.